SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For The Quarter Ended March 31, 1997
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the transition period from to
Commission file number 0-19386
FISCHER IMAGING CORPORATION
(Exact name of Registrant as specified in its charter)
DELAWARE 36-2756787
(State of incorporation) (I.R.S. Employer Identification No.)
12300 North Grant Street
Denver, Colorado 80241
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (303) 452-6800
Indicate by check mark whether the Registrant (i) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the Registrant was
required to file such reports) and (ii) has been subject to such filing
requirements for the past 90 days. Yes X No
--- ---
Shares Outstanding as of
Title of Class March 31, 1997
- ------------------------------ ------------------------
Common Stock, $0.01 par value 6,941,798
<PAGE>
FISCHER IMAGING CORPORATION
TABLE OF CONTENTS
PART I. FINANCIAL INFORMATION PAGE
Item 1. Consolidated Financial Statements
Consolidated Balance Sheets -
March 31, 1997 and December 31, 1996 3
Consolidated Statements of Operations -
Three months ended March 31, 1997 and 1996 4
Consolidated Statements of Cash Flows -
Three months ended March 31, 1997 and 1996 5
Notes to Consolidated Financial Statements 6
Item 2. Management's Discussion and Analysis of Financial
Condition and Results of Operations 9
PART II. OTHER INFORMATION
Item 6. Exhibits and Reports on Form 8-K 14
<PAGE>
FISCHER IMAGING CORPORATION
CONSOLIDATED BALANCE SHEETS
(Amounts in thousands except share data)
<TABLE>
<CAPTION>
March 31, December 31,
1997 1996
----------- -------------
ASSETS (Unaudited)
<S> <C> <C>
CURRENT ASSETS:
Cash and cash equivalents $ 5,335 $ 3,289
Trade accounts receivable, net of allowance for doubtful accounts
of approximately $670 and $641 at March 31, 1997 and
December 31, 1996, respectively 12,985 18,600
Inventories 21,375 23,692
Deferred income taxes 2,267 2,267
Prepaid expenses and other current assets 1,265 1,289
------- -------
Total current assets 43,227 49,137
------- -------
PROPERTY AND EQUIPMENT (at cost):
Manufacturing equipment 8,830 8,198
Office equipment and leasehold improvements 5,147 4,666
------- -------
13,977 12,864
Less- Accumulated depreciation and amortization 8,556 8,294
------- -------
Property and equipment, net 5,421 4,570
------- -------
INTANGIBLE ASSETS, net 4,147 4,327
DEFERRED INCOME TAXES 346 346
DEFERRED COSTS AND OTHER ASSETS 1,894 2,052
------- -------
TOTAL ASSETS $ 55,035 $ 60,432
======= =======
LIABILITIES AND STOCKHOLDERS' INVESTMENT
CURRENT LIABILITIES:
Trade accounts payable $ 3,443 $ 5,155
Notes payable and current maturities of long-term debt 274 283
Accrued salaries and wages 2,227 2,160
Deferred service revenue 830 805
Other current liabilities 3,433 3,587
------- -------
Total current liabilities 10,207 11,990
LONG-TERM DEBT 83 149
OTHER NONCURRENT LIABILITIES 489 488
------- -------
TOTAL LIABILITIES 10,779 12,627
------- -------
STOCKHOLDERS' INVESTMENT:
Common Stock, $.01 par value, 25,000,000 shares authorized, 6,941,798
and 6,920,335 shares issued and outstanding at March 31, 1997 and
December 31, 1996, respectively 69 69
Preferred Stock, 5,000,000 shares authorized:
Series C Junior Participating Preferred Stock, $.01 par value, 500,000 shares
authorized, no shares issued and outstanding - -
Series D Convertible Preferred Stock, $.01 par value, 1,333,333 shares
authorized, issued and outstanding at March 31, 1997 and
December 31, 1996; liquidation preference of $10,000,000 13 13
Additional paid-in capital 49,203 49,093
Accumulated deficit (5,267) (1,388)
Cumulative translation adjustment 238 18
------- -------
TOTAL STOCKHOLDERS' INVESTMENT 44,256 47,805
------- -------
TOTAL LIABILITIES AND STOCKHOLDERS' INVESTMENT $ 55,035 $ 60,432
======= =======
</TABLE>
The accompanying notes are an integral part of these financial statements.
3
<PAGE>
FISCHER IMAGING CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS
(Amounts in thousands except per share data)
(Unaudited)
<TABLE>
<CAPTION>
Three Months Ended
---------------------------------
March 31, March 31,
1997 1996
----------- -----------
<S> <C> <C>
NET REVENUES $ 12,302 $ 20,073
COST OF SALES 8,552 11,588
------ -------
Gross profit 3,750 8,485
OPERATING EXPENSES:
Research and development 1,512 1,464
Selling, marketing and service 4,676 4,358
General and administrative 1,161 1,131
------ -------
Total operating expenses 7,349 6,953
------ -------
(LOSS) EARNINGS FROM OPERATIONS (3,599) 1,532
Interest expense (73) (220)
Interest income 61 9
Other (expense) income, net (268) 102
------ -------
(LOSS) EARNINGS BEFORE INCOME TAXES (3,879) 1,423
Provision for income taxes -- 350
------ -------
NET (LOSS) EARNINGS $ (3,879) $ 1,073
====== =======
NET (LOSS) EARNINGS PER COMMON AND
COMMON EQUIVALENT SHARE $ (.47) $ 0.15
====== =======
WEIGHTED AVERAGE COMMON
AND COMMON EQUIVALENT
SHARES OUTSTANDING 8,275 7,211
====== =======
</TABLE>
The accompanying notes are an integral part of these financial statements.
4
<PAGE>
FISCHER IMAGING CORPORATION
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Amounts in thousands)
(Unaudited)
<TABLE>
<CAPTION>
Three Months Ended
-------------------------
March 31, March 31,
1997 1996
--------- ---------
CASH FLOWS FROM OPERATING ACTIVITIES:
<S> <C> <C>
Net (loss) earnings $ (3,879) $ 1,073
---------- ---------
Adjustments to reconcile net (loss) earnings to net cash
provided by (used in) operating activities-
Depreciation 440 386
Amortization of intangible assets 180 187
Provision for doubtful accounts 2 29
Sales and retirements of assets 30 (7)
Other changes in current assets and liabilities-
Decrease in trade accounts receivable 5,613 738
Decrease (Increase) in inventories 2,317 (1,955)
Decrease in deferred income taxes -- 159
Decrease (Increase) in prepaid expenses and other current assets 24 (327)
Decrease (Increase) in deferred costs and other assets 158 (176)
Decrease in disbursements in transit -- (363)
Decrease in trade accounts payable (1,712) (646)
Increase in accrued salaries and wages 67 55
Increase (Decrease) in deferred service revenue 25 (255)
Decrease in other current liabilities (154) (319)
Other 1 (18)
---------- ---------
Total adjustments (6,991) (2,512)
---------- ---------
Net cash provided by (used in) operating activities 3,112 (1,439)
---------- ---------
CASH FLOWS FROM INVESTING ACTIVITIES:
Capital expenditures (1,321) (407)
Other -- (48)
---------- ---------
Net cash used in investing activities (1,321) (455)
---------- ---------
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from sales of common stock 110 369
Net borrowings under line of credit agreement -- 1,327
Repayments of long-term debt (75) (219)
---------- ---------
Net cash provided by financing activities 35 1,477
---------- ---------
EFFECT OF EXCHANGE RATE CHANGES ON CASH 220 29
---------- ---------
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS 2,046 (388)
CASH AND CASH EQUIVALENTS, beginning of period 3,289 968
---------- ---------
CASH AND CASH EQUIVALENTS, end of period $ 5,335 $ 580
========== =========
</TABLE>
The accompanying notes are an integral part of these financial statements.
5
<PAGE>
FISCHER IMAGING CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
1. GENERAL
In the opinion of management, the accompanying unaudited consolidated balance
sheets and statements of operations and cash flows contain all adjustments,
consisting only of normal recurring items, necessary to present fairly the
financial position of Fischer Imaging Corporation (the "Company") at March 31,
1997, its results of operations for the three months ended March 31, 1997 and
1996 and cash flows for the three months ended March 31, 1997 and 1996.
The unaudited consolidated financial statements presented herein have been
prepared in accordance with the instructions to Form 10-Q and do not include all
the information and note disclosures required by generally accepted accounting
principles. The financial statements should be read in conjunction with the
audited financial statements and notes thereto contained in the Company's latest
annual report on Form 10-K for the year ended December 31, 1996.
The Company typically closes its first three fiscal quarters as of the Sunday
closest to the end of March, June and September. In 1997, to more evenly
distribute the days between quarters, the first three fiscal quarters are being
closed as of the Monday closest to the end of the respective months, or March
31, June 30, and September 29, respectively.
2. INVENTORIES
Inventories include costs of materials, direct labor and manufacturing overhead.
Inventories are priced at the lower of cost (using primarily the last-in,
first-out ("LIFO") method of valuation) or market. Writedowns for excess or
obsolete inventories are charged to expense in the period in which conditions
giving rise to the writedowns are first recognized.
Inventories consisted of the following components (in thousands):
March 31, December 31,
1997 1996
---------------- ------------------
FIFO cost-
Raw materials $ 14,023 $ 16,244
Work in process and finished goods 13,268 13,467
LIFO valuation adjustment (893) (893)
------ ------
Total before valuation reserves 26,398 28,818
Less valuation reserves (5,023) (5,126)
------ ------
Inventories, net $ 21,375 $ 23,692
====== ======
3. OTHER CURRENT LIABILITIES
Other current liabilities consisted of the following (in thousands):
March 31, December 31,
1997 1996
---------------- ------------------
Customer deposits $ 1,400 $ 1,058
Accrued warranty and installation costs 1,333 1,408
Other 700 1,121
------ ------
Total other current liabilities $ 3,433 $ 3,587
===== =====
6
<PAGE>
4. NOTES PAYABLE AND LONG-TERM DEBT
Notes payable and long-term debt consisted of the following (in thousands):
March 31, December 31,
1997 1996
---------------- -----------------
Capitalized lease obligations $ 310 $ 382
Other 47 50
------- -------
357 432
Less--Current maturities (274) (283)
------- -------
Long-term debt $ 83 $ 149
======= =======
See "Management's Discussion & Analysis - Liquidity and Capital Resources" for
an additional discussion of the Company's line of credit.
5. ISSUANCE OF STOCK
On June 27, 1996, the Company completed the sale of 1,200,000 shares of its
common stock at $12.00 per share. Proceeds, net of underwriting discount and
other expenses, of $13,121,000 were received in early July 1996 and were
primarily utilized to repay existing indebtedness under the Company's bank
revolving line of credit of approximately $6.4 million.
The remaining proceeds were invested in short-term, investment grade securities.
6. NET EARNINGS (LOSS) PER COMMON AND COMMON EQUIVALENT SHARE
Net earnings (loss) per share is computed based on the weighted average number
of common and convertible preferred shares and, if dilutive, other common
equivalent shares outstanding during each of the periods. The Company uses the
treasury stock method for determining the effect of outstanding stock options on
earnings per share.
In February 1997, the Financial Accounting Standards Board issued Statement of
Financial Accounting Standards No. 128 "Earnings per Share", which is to be
effective December 15, 1997. This statement establishes standards for computing
and presenting earnings per share. Had this statement been adopted as of March
31, 1997, (loss) earnings per share would have been as follows:
March 31, March 31,
1997 1996
------------------ ------------------
Basic (loss) earnings per share $(.56) $.18
Diluted (loss) earnings per share (.47) .15
7. FISCHER MIDWEST MINORITY INTEREST
During the first quarter of 1996, the Company acquired the 45% minority interest
of Fischer Imaging Midwest, Inc., its domestic marketing subsidiary, in exchange
for shares of the Company's stock. The Company accounted for this transaction as
a purchase, acquiring the minority interest with a net book value of
approximately $331,000 and recording goodwill of approximately $270,000, which
will be amortized on a straight-line basis over 15 years.
7
<PAGE>
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following discussion of results of operations and financial condition
contains forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the Securities Exchange
Act of 1934, as amended. For this purpose, any statements contained herein that
are not statements of historical fact may be deemed to be forward-looking
statements. Without limiting the foregoing, the words "believes", "expects",
"anticipates", "plans", "estimates", and similar words and expressions are
intended to identify forward-looking statements. These forward-looking
statements include statements about the size and growth of the Company's
markets, the Company's future operating results including revenues and expenses,
the success of its cost-cutting measures, the effects of outsourcing and
transferring certain production from the Company's Addison, Illinois facility,
sales under its OEM agreements and otherwise, marketing arrangements for its
Mammotest products and other products, development of new products, submissions
to the FDA and receipt of FDA approvals and clearances, resolutions of
deficiencies noted by the FDA, the availability of sources of liquidity and
capital financing, and other matters. These forward-looking statements involve
risks and uncertainties. The actual results that the Company achieves may differ
materially from those discussed in such forward-looking statements due to the
risks and uncertainties described in this Form 10-Q, in the Business section of
the Company's Form 10-K for the year ended December 31, 1996 (the "Form 10-K")
under the "Risks Associated with OEM Agreements", "Risks of Technological Change
and New Products", "Risks of New Product Development and Market Acceptance",
"Manufacturing and Operating Risks", "Government Regulation", and "Product
Liability, Market Withdrawal, and Product Recalls" headings, in the Management's
Discussion and Analysis of Financial Condition and Results of Operations
("MD&A") section of the Form 10-K and elsewhere in the Form 10-K, as well as in
the "Risk Factors" section of the Company's Registration Statement on Form S-2
that was declared effective on June 27, 1996.
OVERVIEW
The Company designs, manufactures and markets specialty and general purpose
medical imaging systems for the diagnosis and treatment of disease. The
Company's newest product lines are directed towards medical specialties in which
image-guided, minimally-invasive therapies are replacing open surgical
procedures. These products are used primarily in the diagnosis and treatment of
breast cancer, heart disease and vascular disease. The Company also designs and
manufactures specialty x-ray imaging components and subsystems for several
leading medical products companies as an original equipment manufacturer ("OEM")
and sells general radiology systems for use in hospitals, clinics and
physicians' offices.
The Company experienced substantial losses for the three months ended March 31,
1997 and break-even operating results in 1996, with losses in the second half of
the year. The Company cannot predict when it will return to profitability,
although it has taken significant steps to reduce costs and improve sales during
1997. Improvement in the Company's results of operations will depend on many
factors including, among other things, demand for the Company's products and the
ability of the Company to maintain or increase gross margins, control
manufacturing and other costs, enter into distribution agreements for its
Mammotest products and other products, implement its marketing and sales
strategies in the United States and internationally, maintain orders under OEM
agreements, renew OEM agreements on favorable terms and develop and introduce
new products that compete successfully.
8
<PAGE>
The Company experienced decreases in the sales of its Mammotest systems in the
first quarter of 1997. Sales of Mammotest systems during the last six months of
1996 were flat when compared to the comparable six month period of 1995. The
Company is facing, and expects to continue to face, aggressive and successful
competition within the surgical stereotactic core needle breast biopsy market
from U.S. Surgical Corporation. The Company may not regain momentum in this
market until it enters into a distribution partnership that adequately addresses
this market.
The Company also experienced significantly lower sales under its OEM
arrangements during the fourth quarter of 1996 and the first quarter of 1997
than in comparable prior periods, primarily due to decreased shipments of Tilt-C
systems to GE Medical Systems.
The Company believes that improving factory utilization and further reducing
operating expenses will be key elements in its efforts to return to acceptable
levels of profitability. The Company intends to seek, through outsourcing and
transferring the production of certain components of its products during the
upcoming quarters, to significantly reduce production at its Addison, Illinois
facility as a means of reducing its overall manufacturing costs. However, due to
the potential severance and other expenses associated with outsourcing and
transferring production, as well as other factors, there can be no assurance as
to the timing or ultimate success of such efforts.
The Company has experienced and is likely to continue to experience significant
quarterly and annual fluctuations in net revenues, operating results and net
income, depending on such factors as the timing of large system shipments to
customers, the timing of orders under OEM contracts and related manufacturing
and shipment scheduling, new product introductions and new marketing programs by
the Company and its competitors, delays in contract development projects, the
effect of economic conditions on the Company's markets, the effects of managed
healthcare on capital expenditures and reimbursement, increases in marketing and
research costs in relation to sales, regulatory clearance of new products,
seasonal purchasing patterns of hospitals and the timing of purchasing decisions
by customers. Additionally, because the timing of the occurrence of such factors
is difficult to anticipate and many of the Company's costs are fixed, the
Company may not be able to sufficiently reduce its costs in periods when its
revenues are less than anticipated and may suffer unexpected losses or lower
income in these periods.
The Company is attempting to expand its international sales and marketing
efforts, which can be expected to result in losses from its international
operations until its international revenues reach sufficient levels.
Additionally, the Company's exposure to the risks of international business,
including foreign currency risks, may increase as its international business
grows. The Company attempts to minimize these risks through measures including,
but not limited to, requiring payments in U.S. dollars and the use of
dollar-denominated letters of credit. There can be no assurance, however, that
the Company will be successful in its international sales efforts or in
minimizing any associated risks.
9
<PAGE>
The Company is subject to periodic inspections by the Food and Drug
Administration ("FDA") whose primary purpose is to audit the Company's
compliance with Good Manufacturing Practices ("GMPs"), which include testing,
quality control and documentation procedures. Following a December 1996
inspection, the FDA issued Inspectional Observations Form 483 ("Form 483") and a
Warning Letter regarding manufacturing practices at its Denver facility. As
requested, the Company has responded to the Warning Letter regarding planned
corrective actions. By August 1, 1997, the Company must also obtain third-party
certification of the Company's manufacturing and quality systems. Until
outstanding GMP concerns are resolved, the Company will be unable to receive an
award of a federal government contract or new marketing or export clearance for
products manufactured at its Denver facility. Failure to correct the noted
deviations, to obtain third-party certification, and/or other ongoing FDA
concerns could also result in FDA enforcement actions which could include, among
other things, seizure, injunction, and/or criminal or civil proceedings being
initiated without further notice. The Company has also received a Non-Compliance
Declaration from the Center for Device Evaluation and Research ("CDRH")
regarding violations of the Electronic Product Radiation Control Performance
Standard. The Company has responded to the Non-Compliance Declaration describing
planned corrective actions as to some matters and requesting exemption as to
others. The Company believes that it will be able to correct the deficiencies
noted in the Form 483, the FDA Warning Letter, and the CDRH Non-Compliance
Declaration, although no assurance can be given that the corrections can be
accomplished in a timely manner, if at all.
Although the Company strives to operate within the requirements imposed by the
FDA, there can be no assurances that these deficiencies can be corrected or that
the Company will be able to satisfy FDA compliance concerns in the future. These
ongoing compliance reviews and/or related delays in future product clearances
could have a material adverse effect on the Company.
RESULTS OF OPERATIONS
The Company's net revenues and net loss were $12,302,000 and $3,879,000,
respectively, for the first quarter of 1997, as compared to revenues of
$20,073,000 and net earnings of $1,073,000 for the first quarter of 1996. The
most significant factor in the decline in revenues as compared to the first
quarter of 1996 was a greater than 50% decline in OEM shipments, principally
sales of Tilt-C systems to GE Medical Systems. Sales of Mammotest breast biopsy
systems also declined, as did shipments of general and specialty purpose x-ray
systems. The Company's operating results for the first quarter were negatively
affected by these decreased sales and by lower absorption of its fixed
manufacturing costs, which declined primarily as a result of lower levels of
production activity in anticipation of lower shipments and as a result of
planned reductions in inventory levels. See "Overview" for a further discussion
of the recent decline in the Company's sales and the Company's efforts to reduce
its manufacturing costs.
10
<PAGE>
The following table sets forth the percentage of net revenues represented by
certain data included in the Company's statements of operations for the periods
indicated:
Three Months Ended
-------------------------------------
March 31, March 31,
1997 1996
--------- ---------
Net revenues 100.0 % 100.0 %
Gross profit 30.5 42.3
Research and development 12.3 7.3
Selling, marketing and service 38.0 21.7
General and administrative 9.4 5.6
(Loss) Earnings from operations (29.3) 7.6
Provision for income taxes -- 1.7
Net (loss) earnings (31.5) 5.3
Net Revenues. First quarter net revenues were $12,302,000, a decrease of 39%
from first quarter 1996 net revenues of $20,073,000. The Company's decrease in
revenues for the three months ended March 31, 1997 compared to the same period
in 1996 principally reflects a strong decrease in OEM shipments (primarily the
Tilt-C system sold to GE Medical Systems) but also a significant reduction in
sales of Mammotest systems, sold through direct and dealer channels, as well as
reductions in general and specialty purpose x-ray systems. For the three months
ended March 31, 1997, international revenues were approximately 30% lower than
the comparable three months of 1996, principally due to the impact of the strong
dollar on export sales to Europe.
Gross Profit. For the first quarter of 1997, gross profit expressed as a
percentage of net revenues was 30.5%, as compared to the 42.3% for the first
quarter of 1996. The decline in gross profit as a percentage of revenues was due
to an increase in unfavorable manufacturing variances, as a result of a
substantial decline in production caused by the reduction in OEM and other
shipments and by the Company's successful efforts to reduce inventory levels.
The effects of increased unfavorable manufacturing variances were partly offset
by a shift in product mix from OEM shipments to proprietary products and service
revenues, which generally have higher margins.
Research and Development Expenses. Research and development expenses for the
first quarter of 1997 and 1996 were $1,512,000 and $1,464,000, respectively. The
higher level of research and development expenses over last year is primarily
attributable to engineering efforts temporarily assigned to product enhancement
and other production activities in the first quarter of 1996. As a percentage of
net revenues, first quarter 1997 and 1996 research and development expenses were
12.3% and 7.3%, respectively. The increase as a percentage of net revenues is
due to the impact of research and development efforts temporarily assigned to
production activities in 1996 and to lower net revenues in the first quarter of
1997.
11
<PAGE>
Selling, Marketing and Service Expenses. Selling, marketing and service expenses
for the first quarter of 1997 and 1996 were $4,676,000 and $4,358,000,
respectively, or 38.0% and 21.7%, respectively, of net revenues. The increase in
selling, marketing and service expense for the three months ended March 31, 1997
as compared to the same three months of 1996 and as a percentage of net revenues
reflects increases in expenses relating to sales through the direct sales
channel, for which the Company incurs commissions, warranty and installation
expenses.
General and Administrative Expenses. General and administrative expenses for the
first quarter of 1997 and 1996 were essentially unchanged at $1,161,000 and
$1,131,000, respectively. As a percentage of net revenues, general and
administrative expenses increased from 5.6% to 9.4% from the first quarter of
1996 to the first quarter of 1997. The increase in general and administrative
expenses as a percentage of net revenues is primarily due to the change in net
revenues, which decreased significantly in 1997 as compared to 1996.
Interest Expense / Interest Income. Interest expense for the first quarter of
1997 and 1996 was $73,000 and $220,000, respectively. Interest income for the
first quarter of 1997 and 1996 was $61,000 and $9,000, respectively. The
reduction in interest expense is principally related to changes in outstanding
borrowings under the Company's revolving line of credit and other borrowing
arrangements. The Company's borrowings under its line of credit have been
primarily a function of working capital requirements, which have decreased as a
result of lower revenues and the use of proceeds from sales of Company stock to
repay existing indebtedness under the line of credit. The increase in interest
income is primarily due to average cash and cash equivalent borrowings, which
have increased as a result of the investment in short-term, investment grade
securities of the proceeds from the sale of common stock that were not utilized
to repay existing indebtedness in 1996. (See Note 5.)
Net (Loss) Earnings. The Company's net loss for the first quarter of 1997 was
$3,879,000 as compared to net earnings of $1,073,000 for the first quarter of
1996. For the three month period ended March 31, 1997, operating results were
unfavorably impacted by the reductions in gross margin resulting from lower
sales and higher unfavorable manufacturing variances, marketing and service
expenses associated with sales through the direct sales channel, and the
unfavorable effects of foreign translation losses caused by the strengthening
U.S. dollar as comparable period in 1996.
INCOME TAXES
The Company's estimated effective tax rate for the year ended December 31, 1997
is currently 0%. Accordingly, no income tax benefit has been provided for the
three months ended March 31, 1997. This rate was determined based upon the
anticipated 1997 results of operations of companies in the domestic consolidated
tax return and upon projected net temporary differences between operating
results reflected in the financial statements and those required to be reflected
in the domestic consolidated tax return for 1997. As of December 31, 1996, the
Company had approximately $2,613,000 of net deferred tax assets, which
represents credits that are more likely than not to be realized against taxable
income of future years. The amount of net deferred tax asset considered
realizable, however, could be reduced in the near term if estimates of future
taxable income do not materialize.
No income tax provisions have been recognized for foreign tax jurisdictions and
no income tax benefits have been recognized for subsidiary losses outside the
domestic consolidated return because they are not expected to reverse in the
foreseeable future.
12
<PAGE>
LIQUIDITY AND CAPITAL RESOURCES
Net cash provided by operating activities for the three months ended March 31,
1997 was $3.1 million compared to $1.4 million used in operations in the
comparable period of 1996. The generation of cash flow from operations was
primarily due to a decrease in working capital. This decrease in working capital
was the result of $5.6 million in net collections of trade accounts receivable
and a reduced investment in inventories of $2.3 million, partially offset by a
$1.7 million reduction in trade accounts payable. The decrease in working
capital investment was partially offset by a net loss before depreciation and
amortization of $3.7 million.
Net cash used in investing activities was $1.3 million for the three months
ended March 31, 1997, compared to $0.5 million for the same period in 1996. The
increase was principally related to capital equipment investments related to
digital mammography.
Net cash provided by financing activities for the three months ended March 31,
1997 was $0, compared to $1.5 million for the same period in 1996. The amount
provided from financing activities for the three months ended March 31, 1996 was
primarily due to net borrowings under the Company's line of credit, which were
related to increased working capital requirements during that period. During the
comparable period of 1997, no financing was required, due primarily to
reductions in required investment in working capital.
As of March 31, 1997, the Company had $5.3 million in cash and cash equivalents
and working capital of $33.0 million. As of March 31, 1997, the Company had no
outstanding borrowings under any line of credit arrangements. The Company is
currently negotiating a working capital line of credit. The borrowings under the
line of credit are expected to be secured by accounts receivable, inventory and
fixed assets and to be subject to borrowing base restrictions. The Company
expects its long-term liquidity needs to be satisfied principally from cash
flows generated from operations. The Company believes that its short-term
liquidity needs can be satisfied through cash provided from operations and
current cash and cash equivalent balances if a working capital line of credit is
not finalized or finalization is delayed.
13
<PAGE>
PART II. OTHER INFORMATION
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K:
(A) EXHIBITS
Exhibits filed with this report:
`
EXHIBIT NO. DESCRIPTION
27 Financial Data Schedule
(B) REPORTS ON FORM 8-K
None
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this Quarterly Report on Form 10-Q for the quarter
ended March 31, 1997 to be signed on its behalf by the undersigned thereunto
duly authorized.
FISCHER IMAGING CORPORATION
/S/ JAMES A. NEWCOMB
-------------------------------
James A. Newcomb
Vice President Finance /
Chief Financial Officer
(Principal Financial
and Accounting Officer)
May 15, 1997
14
<PAGE>
EXHIBIT INDEX
EXHIBIT NO. DESCRIPTION
27 Financial Data Schedule
<TABLE> <S> <C>
<ARTICLE> 5
<MULTIPLIER> 1000
<S> <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END> DEC-31-1997
<PERIOD-END> MAR-31-1997
<CASH> 5,335
<SECURITIES> 0
<RECEIVABLES> 13,655
<ALLOWANCES> 670
<INVENTORY> 21,375
<CURRENT-ASSETS> 43,227
<PP&E> 13,977
<DEPRECIATION> 8,556
<TOTAL-ASSETS> 55,035
<CURRENT-LIABILITIES> 10,207
<BONDS> 83
0
13
<COMMON> 69
<OTHER-SE> 44,174
<TOTAL-LIABILITY-AND-EQUITY> 55,035
<SALES> 12,302
<TOTAL-REVENUES> 12,302
<CGS> 8,552
<TOTAL-COSTS> 8,552
<OTHER-EXPENSES> 7,349
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 73
<INCOME-PRETAX> (3,879)
<INCOME-TAX> 0
<INCOME-CONTINUING> (3,879)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (3,879)
<EPS-PRIMARY> (.47)
<EPS-DILUTED> (.47)
</TABLE>
